Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 285

Related Citations for PubMed (Select 22975733)

1.

Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI.

Suzuki T, Horikoshi M, Sugihara M, Hirota T, Ogishima H, Umeda N, Kondo Y, Tsuboi H, Hayashi T, Chino Y, Matsumoto I, Sumida T.

Mod Rheumatol. 2013 Jul;23(4):782-7. doi: 10.1007/s10165-012-0746-2. Epub 2012 Sep 14.

PMID:
22975733
2.

A new low-field extremity magnetic resonance imaging and proposed compact MRI score: evaluation of anti-tumor necrosis factor biologics on rheumatoid arthritis.

Suzuki T, Ito S, Handa S, Kose K, Okamoto Y, Minami M, Hayashi T, Goto D, Matsumoto I, Sumida T.

Mod Rheumatol. 2009;19(4):358-65. doi: 10.1007/s10165-009-0172-2. Epub 2009 Apr 16.

4.

Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.

Shimamoto K, Ito T, Ozaki Y, Amuro H, Tanaka A, Nishizawa T, Son Y, Inaba M, Nomura S.

J Rheumatol. 2013 Jul;40(7):1074-81. doi: 10.3899/jrheum.121389. Epub 2013 May 1.

PMID:
23637318
5.

Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors.

Tanaka Y, Takeuchi T, Amano K, Saito K, Hanami K, Nawata M, Fukuyo S, Kameda H, Kaneko Y, Kurasawa T, Nagasawa H, Hoshi D, Sato E, Yamanaka H.

Mod Rheumatol. 2014 May;24(3):399-404. doi: 10.3109/14397595.2013.843757. Epub 2013 Nov 5.

PMID:
24252045
6.
7.

The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy.

Conaghan PG, Peterfy C, Olech E, Kaine J, Ridley D, Dicarlo J, Friedman J, Devenport J, Troum O.

Ann Rheum Dis. 2014 May;73(5):810-6. doi: 10.1136/annrheumdis-2013-204762. Epub 2014 Feb 13.

8.

Switching to the anti-interleukin-6 receptor antibody tocilizumab in rheumatoid arthritis patients refractory to antitumor necrosis factor biologics.

Kawashiri SY, Kawakami A, Iwamoto N, Fujikawa K, Aramaki T, Tamai M, Arima K, Ichinose K, Kamachi M, Yamasaki S, Nakamura H, Origuchi T, Ida H, Eguchi K.

Mod Rheumatol. 2010 Feb;20(1):40-5. doi: 10.1007/s10165-009-0235-4. Epub 2009 Oct 3.

PMID:
19802651
9.

Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis.

Kojima T, Yabe Y, Kaneko A, Hirano Y, Ishikawa H, Hayashi M, Miyake H, Takagi H, Kato T, Terabe K, Wanatabe T, Tsuchiya H, Kida D, Shioura T, Funahashi K, Kato D, Matsubara H, Takahashi N, Hattori Y, Asai N, Ishiguro N.

Mod Rheumatol. 2013 Sep;23(5):977-85. doi: 10.1007/s10165-012-0782-y. Epub 2012 Oct 26.

PMID:
23099471
10.

Rapid reduction in tenosynovitis of the wrist and fingers evaluated by MRI in patients with rheumatoid arthritis after treatment with etanercept.

Lisbona MP, Maymó J, Perich J, Almirall M, Carbonell J.

Ann Rheum Dis. 2010 Jun;69(6):1117-22. doi: 10.1136/ard.2009.116277. Epub 2010 May 6.

PMID:
20448287
11.

Persistent periodontal disease hampers anti-tumor necrosis factor treatment response in rheumatoid arthritis.

Savioli C, Ribeiro AC, Fabri GM, Calich AL, Carvalho J, Silva CA, Viana VS, Bonfá E, Siqueira JT.

J Clin Rheumatol. 2012 Jun;18(4):180-4. doi: 10.1097/RHU.0b013e31825828be.

PMID:
22647860
12.

Continued benefit of tocilizumab plus disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis and inadequate clinical responses by week 8 of treatment.

Keystone EC, Anisfeld A, Ogale S, Devenport JN, Curtis JR.

J Rheumatol. 2014 Feb;41(2):216-26. doi: 10.3899/jrheum.130489. Epub 2014 Jan 15.

13.

Rapid improvement in rheumatoid arthritis patients on combination of methotrexate and infliximab: clinical and magnetic resonance imaging evaluation.

Tam LS, Griffith JF, Yu AB, Li TK, Li EK.

Clin Rheumatol. 2007 Jun;26(6):941-6. Epub 2006 Jul 26.

PMID:
16868816
14.

Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate.

Nakashima Y, Kondo M, Harada H, Horiuchi T, Ishinishi T, Jojima H, Kuroda K, Miyahara H, Nagamine R, Nakashima H, Otsuka T, Saikawa I, Shono E, Suematsu E, Tsuru T, Wada K, Iwamoto Y.

Mod Rheumatol. 2010 Aug;20(4):343-52. doi: 10.1007/s10165-010-0290-x. Epub 2010 May 18.

PMID:
20480201
15.

Magnetic resonance imaging quantification of hand synovitis in patients with rheumatoid arthritis treated with adalimumab.

Zikou AK, Argyropoulou MI, Voulgari PV, Xydis VG, Nikas SN, Efremidis SC, Drosos AA.

J Rheumatol. 2006 Feb;33(2):219-23.

PMID:
16465650
16.

Very early improvements in the wrist and hand assessed by power Doppler sonography predicting later favorable responses in tocilizumab-treated patients with rheumatoid arthritis.

Kume K, Amano K, Yamada S, Hatta K, Kuwaba N, Ohta H.

Arthritis Care Res (Hoboken). 2011 Oct;63(10):1477-81. doi: 10.1002/acr.20537.

PMID:
21702090
18.

Persistent low grade synovitis without erosive progression in magnetic resonance imaging of rheumatoid arthritis patients treated with infliximab over 1 year.

Fonseca JE, Canhão H, Tavares NJ, Cruz M, Branco J, Queiroz MV.

Clin Rheumatol. 2009 Oct;28(10):1213-6. doi: 10.1007/s10067-009-1207-y. Epub 2009 Jun 6.

PMID:
19504146
19.

Efficacy and safety of tocilizumab in refractory rheumatoid arthritis: a real life cohort from a single centre.

Addimanda O, Possemato N, Macchioni P, Salvarani C.

Clin Exp Rheumatol. 2014 Jul-Aug;32(4):460-4. Epub 2014 Jun 23.

PMID:
24960220
20.

Response of early active rheumatoid arthritis to tumor necrosis factor inhibitors: evaluation by magnetic resonance imaging.

Hirose W, Nishikawa K, Hirose M, Nanki T, Sugimoto H.

Mod Rheumatol. 2009;19(1):20-6. doi: 10.1007/s10165-008-0114-4. Epub 2008 Sep 2.

PMID:
18762862
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk